Phio Pharmaceuticals
PHIO

股本结构

单位：万股
公告日期 2025-11-13 2025-11-06 2025-11-13 2025-08-14 2025-08-14 2025-05-15
证券总股本 1076.44 819.23 578.48 572.68 479.82 479.82
普通股本 1076.44 819.23 578.48 572.68 479.82 479.82
优先股 未披露 未披露 未披露 未披露 未披露 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2025-11-11 2025-11-03 2025-09-30 2025-08-12 2025-06-30 2025-05-15
注释：中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本（万股） 变动后优先股（万股） 变动原因 变动日期
2025-11-13 1076.44 未披露 定期报告 2025-11-11
2025-11-06 819.23 未披露 定期报告 2025-11-03
2025-11-13 578.48 未披露
更多>>
From June 30, 2025 to September 30, 2025 Issuance of common stock upon vesting of restricted stock units Issuance of common stock upon exercise of warrants Issuance of common stock and warrants, net of offering costs of $435 Shares withheld for payroll taxes
2025-09-30
2025-08-14 572.68 未披露 定期报告 2025-08-12
2025-08-14 479.82 未披露
更多>>
From March 31, 2025 to June 30, 2025 Issuance of common stock upon exercise of warrants
2025-06-30
2025-05-15 479.82 未披露 定期报告 2025-05-15
2025-05-15 477.82 未披露
更多>>
From December 31, 2024 to March 31, 2025 Issuance of common stock upon exercise of warrants Issuance of common stock and warrants
2025-03-31
2025-03-31 477.82 未披露 定期报告 2025-03-20
2025-01-17 477.68 未披露
更多>>
Common stock offered 610,000 shares of Common Stock.
2025-01-17
2025-01-15 416.68 未披露
更多>>
Common stock offered 833,335 shares of Common Stock by the company
2025-01-15
2025-01-15 333.35 未披露
更多>>
Common stock offered 1,063,670 shares of Common Stock by the company
2025-01-14
2025-03-31 173.37 未披露
更多>>
From December 31, 2023 to December 31, 2024 Issuance of common stock upon exercise of warrants Issuance of common stock upon vesting of restricted stock units Shares withheld for payroll taxes Cash issued in lieu of fractional shares for 1:9 reverse stock split Issuance of common stock and warrants, net of offering costs
2024-12-31
2024-12-23 173.24 未披露
更多>>
Common stock offered 240,000 shares of Common Stock by the company
2024-12-24
2024-12-20 149.24 未披露
更多>>
Common stock offered 437,192 shares of Common Stock by the company
2024-12-20
2024-11-14 105.52 未披露 定期报告 2024-11-14
2024-11-14 95.82 未披露
更多>>
From June 30, 2024 to September 30, 2024 Issuance of common stock and warrants, net of offering costs Issuance of common stock upon exercise of warrants Cash-in-lieu of fractional shares for reverse stock split
2024-09-30
2024-08-14 86.07 未披露 定期报告 2024-08-02
2024-07-26 185.79 未披露 定期报告 2024-07-17
2024-07-02 50.00 未披露
更多>>
a reverse stock split of its shares of common stock at a ratio of 1-for-9
2024-07-05
2024-07-02 460.00 未披露 定期报告 2024-07-02
2024-05-09 459.17 未披露
更多>>
From December 31, 2023 to March 31, 2024 Issuance of common stock upon exercise of warrants Shares withheld for payroll taxes Issuance of common stock upon vesting of restricted stock units
2024-03-31
2024-04-01 459.17 未披露 定期报告 2024-03-15
2024-04-01 374.73 未披露
更多>>
From December 31, 2022 to December 31, 2023 Cash-in-lieu of fractional shares for reverse stock split Issuance of common stock and warrants, net of offering costs Issuance of common stock upon exercise of warrants Issuance of common stock upon vesting of restricted stock units Shares withheld for payroll taxes Redemption of preferred stock
2023-12-31
2023-11-09 244.34 未披露 定期报告 2023-11-03
2023-11-09 230.74 未披露
更多>>
From June 30, 2023 to September 30, 2023 Issuance of common stock upon exercise of warrants Shares withheld for payroll taxes Issuance of common stock upon vesting of restricted stock units
2023-09-30
2023-08-10 222.19 未披露 定期报告 2023-08-04
2023-08-10 198.52 未披露
更多>>
From March 31, 2023 to June 30, 2023 Issuance of common stock and warrants, net of offering costs Issuance of common stock upon exercise of warrants
2023-06-30
2023-06-01 173.82 未披露
更多>>
Common stock offered 233,646 shares by the company
2023-06-02
2023-04-19 150.46 未披露
更多>>
Common stock offered 353,983 shares by the company
2023-04-20
2023-05-11 115.06 未披露
更多>>
From December 31, 2022 to March 31, 2023 Shares withheld for payroll taxes Redemption of preferred stock Issuance of common stock upon vesting of restricted stock units Cash-in-lieu of fractional shares for reverse stock split
2023-03-31
2023-03-22 115.06 未披露 定期报告 2023-03-09
2023-01-25 110.00 未披露
更多>>
Thereafter, on January 24, 2023, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, to implement the 1-for-12 reverse split of its common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every twelve (12) shares of the Company’s issued and outstanding common stock, par value $0.0001, will be converted into one (1) share of common stock, par value $0.0001, reducing the number of issued and outstanding shares of the Company’s common stock from approximately 13.7 million shares to approximately 1.1 million shares.
2023-01-26
2022-11-10 1366.80 未披露
更多>>
From June 30, 2022 to September 30, 2022 Issuance of common stock upon vesting of restricted stock units Shares withheld for payroll taxes
2022-09-30
2022-05-12 1365.87 未披露
更多>>
From December 31, 2021 to March 31, 2022 Issuance of common stock upon vesting of restricted stock units Shares withheld for payroll taxes
2022-03-31
2022-03-22 1353.50 未披露
更多>>
From December 31, 2020 to December 31, 2021 Issuance of common stock, pre-funded warrants and warrants in connection with private placement, net of offering costs Issuance of common stock in registered direct offering, net of offering costs Issuance of common stock upon the exercise of warrants Issuance of common stock upon vesting of restricted stock units
2021-12-31
2021-11-10 1353.47 未披露
更多>>
From June 30, 2021 to September 30, 2021 Issuance of common stock upon vesting of restricted stock units
2021-09-30
2021-05-13 1353.44 未披露
更多>>
From December 31, 2020 to March 31, 2021 Issuance of common stock, pre-funded warrants and warrants in connection with private placement, net of offering costs of $1,333 Issuance of common stock in registered direct offering, net of offering costs of $776 Issuance of common stock upon the exercise of warrants Issuance of common stock upon vesting of restricted stock units
2021-03-31
2021-04-30 1353.19 未披露 定期报告 2021-03-15
2021-02-17 802.73 未披露
更多>>
1.Common stock offered by this prospectus supplement: 2,246,784 shares. 2.The number of shares of Common Stock to be outstanding after this offering is based on 5,780,533 shares of Common Stock outstanding as of September 30, 2020.
2021-02-17
2021-02-17 1107.02 未披露 定期报告 2021-02-12
2021-01-29 1020.18 未披露 定期报告 2021-01-25
2021-03-25 578.10 未披露
更多>>
From December 31, 2019 to December 31, 2020 Cash in lieu of fractional shares for 1:55 reverse stock split Issuance of common stock under employee stock purchase plan Issuance of common stock and warrants in connection with registered direct and private placement offerings, net of offering costs of $746 Issuance of common stock, pre-funded warrants and warrants in connection with underwritten public offering, net of offering costs of $906 Issuance of common stock upon the exercise of warrants Issuance of common stock upon vesting of restricted stock units
2020-12-31
2020-11-10 578.06 未披露 定期报告 2020-11-06
2020-11-10 578.05 未披露
更多>>
From June 30, 2020 to August 18, 2020 Issuance of common stock upon vesting of restricted stock units
2020-08-18
2020-08-12 578.02 未披露
更多>>
From March 31, 2020 to June 30, 2020 Issuance of common stock and warrants in connection with registered direct and private placement offerings, net of offering costs of $473 Issuance of common stock upon the exercise of warrants Issuance of common stock upon vesting of restricted stock units
2020-06-30
2020-05-12 458.09 未披露 定期报告 2020-05-08
2020-05-12 286.79 未披露
更多>>
From December 31, 2019 to March 20, 2020 Issuance of common stock under employee stock purchase plan Cash in lieu of fractional shares for 1:55 reverse stock split Issuance of common stock and warrants in connection with registered direct and private placement offerings, net of offering costs of $273 Issuance of common stock, pre-funded warrants and warrants in connection with underwritten public offering, net of offering costs of $906 Issuance of common stock upon the exercise of pre-funded warrants Issuance of common stock upon vesting of restricted stock units
2020-03-20
2020-02-13 246.64 未披露
更多>>
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, today announced the pricing of an underwritten public offering of an aggregate of 2,000,000 units at a public offering price of $4.00 per unit. Each unit contains one share of common stock (or common stock equivalent) and one warrant to purchase one share of common stock.
2020-02-13
2020-02-06 66.35 未披露 定期报告 2020-02-06
2020-03-26 66.94 未披露
更多>>
From December 31, 2018 to January 15, 2020 Issuance of common stock upon the exercise of pre-funded warrants Issuance of common stock under Lincoln Park Capital, LLC purchase agreement Issuance of restricted stock Issuance of common stock under employee stock purchase plan Issuance of common stock in connection with registered direct public offering, net of offering costs of $234 Issuance of common stock upon vesting of restricted stock units the Board determined to fix the ratio for the reverse stock split at 1-for-55
2020-01-15
2019-11-22 3681.90 未披露 定期报告 2019-11-19
2019-11-12 2640.47 未披露 定期报告 2019-11-08
2019-11-12 2565.47 未披露
更多>>
from June 30, 2019 to September 30, 2019 Issuance of common stock under Lincoln Park Capital, LLC purchase agreement, net of offering costs of $52 Issuance of common stock upon vesting of restricted stock units
2019-09-30
2019-08-12 2559.12 未披露 定期报告 2019-08-09
2019-08-12 2509.12 未披露
更多>>
from March 31, 2019 to June 30,2019 Issuance of common stock upon the exercise of pre-funded warrants Issuance of common stock under the employee stock purchase plan
2019-06-30
2019-05-14 2388.91 未披露 定期报告 2019-05-10
2019-05-14 2338.91 未披露
更多>>
from December 31, 2018 to March 31, 2019 Issuance of common stock upon the exercise of pre-funded warrants Issuance of restricted stock
2019-03-31
2019-03-27 2229.91 未披露 定期报告 2019-03-22
2019-03-27 1884.18 未披露
更多>>
from December 31, 2017 to December 31, 2018 Cash paid in lieu of fractional shares for 1:10 reverse stock split Issuance of common stock under 2017 Lincoln Park Capital, LLC purchase agreement Issuance of common stock and warrants in connection with registered direct offering and private placement, net of offering costs of $690 Issuance of common stock, pre-funded warrants and warrants in connection with underwritten public offering, net of offering costs of $1,630 Issuance of common stock upon the exercise of pre-funded warrants Issuance of common stock under employee stock purchase plan Issuance of unvested, restricted stock
2018-12-31
2018-11-14 1816.44 未披露 定期报告 2018-11-09
2018-11-14 444.99 未披露 定期报告 2018-09-30
2018-08-14 437.63 未披露 定期报告 2018-08-10
2018-08-14 436.06 未披露 定期报告 2018-06-30
2018-04-26 425.56 未披露 定期报告 2018-04-12
2018-05-10 270.00 未披露 定期报告 2018-03-31
2018-03-29 270.00 未披露 定期报告 2018-03-28
2018-03-26 259.50 未披露 定期报告 2018-03-15
2018-01-05 240.00 未披露
更多>>
RXi Pharmaceuticals Corporation today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 12:01 a.m. Eastern Time on January 8, 2018, and shares of RXi Pharmaceuticals common stock will trade on a post-split basis on the Nasdaq Capital Market under the Company’s existing trading symbol, “RXII,” at the market open on January 8, 2018.At the effective time of the reverse stock split, every ten (10) shares of RXi Pharmaceuticals common stock will be combined into one (1) share of RXi Pharmaceuticals common stock. This will reduce the Company’s issued and outstanding common stock from approximately 24.3 million shares to approximately 2.4 million shares.
2018-01-08
2017-11-08 2369.73 未披露 定期报告 2017-09-30
2017-07-14 2324.73 未披露 定期报告 2017-07-05
2017-08-10 2324.62 未披露 定期报告 2017-06-30
2017-04-27 2212.80 未披露 定期报告 2017-04-17
2017-05-11 2204.55 108.79 定期报告 2017-03-31
2017-03-30 2204.55 未披露 定期报告 2017-03-15
2017-03-30 1300.32 0.57
更多>>
From December 31, 2015 to December 31, 2016 Issuance of common stock under Lincoln Park Capital, LLC purchase agreement Issuance of common stock and warrants in connection with 2016 public offering, net of offering costs of $431 Issuance of Series B convertible preferred stock and warrants in connection with 2016 public offering, net of offering costs of $1,018 Conversions of Series B convertible preferred stock into common stock RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10.
2016-12-31
2016-10-21 659.98 未披露 定期报告 2016-09-30
2016-08-11 655.98 未披露 定期报告 2016-08-05
2016-05-12 653.48 未披露
更多>>
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10.
2016-04-18
2016-03-30 6534.91 未披露
更多>>
From December 31, 2014 to December 31, 2015 Issuance of common stock under Lincoln Park Capital, LLC purchase agreement Issuance of common stock in exchange for patent and technology rights Issuance of common stock in connection with public offering, net of offering costs of $1,198 Issuance of common stock under employee stock purchase plan Issuance of common stock upon exercise of warrants in connection with public offering Dividends issued on Series A and Series A-1 convertible preferred stock Exchange of Series A convertible preferred stock into Series A-1 convertible preferred stock Conversions of Series A and Series A-1 convertible preferred stock into common stock
2015-12-31
2015-11-12 6534.91 未披露 定期报告 2015-11-06
2015-08-12 6494.91 未披露 定期报告 2015-06-30
2015-05-13 3616.01 未披露 定期报告 2015-05-08
2015-04-13 3122.16 0.31 定期报告 2015-03-31
2015-03-30 3122.16 未披露 定期报告 2015-03-30
2015-03-30 2198.43 0.67
更多>>
from December 31, 2013 to December 31, 2014 Exchange of Series A convertible preferred stock into Series A-1 convertible preferred stock Conversions of Series A and Series A-1 convertible preferred stock into common stock Dividends issued on Series A and Series A-1 convertible preferred stock Issuance of common stock, net of offering costs of $114 Issuance of common stock under employee stock purchase plan
2014-12-31
2014-11-13 2113.20 0.69 定期报告 2014-09-30
2014-08-14 1610.33 未披露 定期报告 2014-08-08
2014-08-14 1489.92 0.93 定期报告 2014-06-30
2014-05-14 1402.72 未披露 定期报告 2014-05-09
2014-05-14 1342.72 0.95 定期报告 2014-03-31
2014-03-28 1337.32 未披露 定期报告 2014-03-21
2014-04-23 1688.80 未披露 定期报告 2014-02-10
2014-03-28 1178.80 1.00
更多>>
from December 31,2012 to December 31,2013 Exchange of Series A convertible preferred stock into Series A-1 convertible preferred stock Conversions of Series A and Series A-1 convertible preferred stock into common stock Dividends issued on Series A and Series A-1 convertible preferred stock Issuance of common stock, net of offering costs of $727 Issuance of common stock in exchange for patent and technology rights Cash paid in lieu of fractional shares for 1:30 reverse stock split Common stock issued upon exercise of stock options Issuance of common stock under employee stock purchase plan
2013-12-31
2013-11-14 1168.42 0.98
更多>>
from December 31, 2012 to September 30, 2013 Exchange of Series A convertible preferred stock into Series A-1 convertible preferred stock Conversions of Series A and Series A-1 convertible preferred stock into common stock Dividends issued on Series A and Series A-1 convertible preferred stock Issuance of common stock, net of offering costs of $727 Issuance of common stock in exchange for patent and technology rights Cash paid in lieu of fractional shares for 1:30 reverse stock split Common stock issued upon exercise of stock options
2013-09-30
From June 30, 2025 to September 30, 2025 Issuance of common stock upon vesting of restricted stock units Issuance of common stock upon exercise of warrants Issuance of common stock and warrants, net of offering costs of $435 Shares withheld for payroll taxes
From March 31, 2025 to June 30, 2025 Issuance of common stock upon exercise of warrants
From December 31, 2024 to March 31, 2025 Issuance of common stock upon exercise of warrants Issuance of common stock and warrants
Common stock offered 610,000 shares of Common Stock.
Common stock offered 833,335 shares of Common Stock by the company
Common stock offered 1,063,670 shares of Common Stock by the company
From December 31, 2023 to December 31, 2024 Issuance of common stock upon exercise of warrants Issuance of common stock upon vesting of restricted stock units Shares withheld for payroll taxes Cash issued in lieu of fractional shares for 1:9 reverse stock split Issuance of common stock and warrants, net of offering costs
Common stock offered 240,000 shares of Common Stock by the company
Common stock offered 437,192 shares of Common Stock by the company
From June 30, 2024 to September 30, 2024 Issuance of common stock and warrants, net of offering costs Issuance of common stock upon exercise of warrants Cash-in-lieu of fractional shares for reverse stock split
a reverse stock split of its shares of common stock at a ratio of 1-for-9
From December 31, 2023 to March 31, 2024 Issuance of common stock upon exercise of warrants Shares withheld for payroll taxes Issuance of common stock upon vesting of restricted stock units
From December 31, 2022 to December 31, 2023 Cash-in-lieu of fractional shares for reverse stock split Issuance of common stock and warrants, net of offering costs Issuance of common stock upon exercise of warrants Issuance of common stock upon vesting of restricted stock units Shares withheld for payroll taxes Redemption of preferred stock
From June 30, 2023 to September 30, 2023 Issuance of common stock upon exercise of warrants Shares withheld for payroll taxes Issuance of common stock upon vesting of restricted stock units
From March 31, 2023 to June 30, 2023 Issuance of common stock and warrants, net of offering costs Issuance of common stock upon exercise of warrants
Common stock offered 233,646 shares by the company
Common stock offered 353,983 shares by the company
From December 31, 2022 to March 31, 2023 Shares withheld for payroll taxes Redemption of preferred stock Issuance of common stock upon vesting of restricted stock units Cash-in-lieu of fractional shares for reverse stock split
Thereafter, on January 24, 2023, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, to implement the 1-for-12 reverse split of its common stock (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every twelve (12) shares of the Company’s issued and outstanding common stock, par value $0.0001, will be converted into one (1) share of common stock, par value $0.0001, reducing the number of issued and outstanding shares of the Company’s common stock from approximately 13.7 million shares to approximately 1.1 million shares.
From June 30, 2022 to September 30, 2022 Issuance of common stock upon vesting of restricted stock units Shares withheld for payroll taxes
From December 31, 2021 to March 31, 2022 Issuance of common stock upon vesting of restricted stock units Shares withheld for payroll taxes
From December 31, 2020 to December 31, 2021 Issuance of common stock, pre-funded warrants and warrants in connection with private placement, net of offering costs Issuance of common stock in registered direct offering, net of offering costs Issuance of common stock upon the exercise of warrants Issuance of common stock upon vesting of restricted stock units
From June 30, 2021 to September 30, 2021 Issuance of common stock upon vesting of restricted stock units
From December 31, 2020 to March 31, 2021 Issuance of common stock, pre-funded warrants and warrants in connection with private placement, net of offering costs of $1,333 Issuance of common stock in registered direct offering, net of offering costs of $776 Issuance of common stock upon the exercise of warrants Issuance of common stock upon vesting of restricted stock units
1.Common stock offered by this prospectus supplement: 2,246,784 shares. 2.The number of shares of Common Stock to be outstanding after this offering is based on 5,780,533 shares of Common Stock outstanding as of September 30, 2020.
From December 31, 2019 to December 31, 2020 Cash in lieu of fractional shares for 1:55 reverse stock split Issuance of common stock under employee stock purchase plan Issuance of common stock and warrants in connection with registered direct and private placement offerings, net of offering costs of $746 Issuance of common stock, pre-funded warrants and warrants in connection with underwritten public offering, net of offering costs of $906 Issuance of common stock upon the exercise of warrants Issuance of common stock upon vesting of restricted stock units
From June 30, 2020 to August 18, 2020 Issuance of common stock upon vesting of restricted stock units
From March 31, 2020 to June 30, 2020 Issuance of common stock and warrants in connection with registered direct and private placement offerings, net of offering costs of $473 Issuance of common stock upon the exercise of warrants Issuance of common stock upon vesting of restricted stock units
From December 31, 2019 to March 20, 2020 Issuance of common stock under employee stock purchase plan Cash in lieu of fractional shares for 1:55 reverse stock split Issuance of common stock and warrants in connection with registered direct and private placement offerings, net of offering costs of $273 Issuance of common stock, pre-funded warrants and warrants in connection with underwritten public offering, net of offering costs of $906 Issuance of common stock upon the exercise of pre-funded warrants Issuance of common stock upon vesting of restricted stock units
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, today announced the pricing of an underwritten public offering of an aggregate of 2,000,000 units at a public offering price of $4.00 per unit. Each unit contains one share of common stock (or common stock equivalent) and one warrant to purchase one share of common stock.
From December 31, 2018 to January 15, 2020 Issuance of common stock upon the exercise of pre-funded warrants Issuance of common stock under Lincoln Park Capital, LLC purchase agreement Issuance of restricted stock Issuance of common stock under employee stock purchase plan Issuance of common stock in connection with registered direct public offering, net of offering costs of $234 Issuance of common stock upon vesting of restricted stock units the Board determined to fix the ratio for the reverse stock split at 1-for-55
from June 30, 2019 to September 30, 2019 Issuance of common stock under Lincoln Park Capital, LLC purchase agreement, net of offering costs of $52 Issuance of common stock upon vesting of restricted stock units
from March 31, 2019 to June 30,2019 Issuance of common stock upon the exercise of pre-funded warrants Issuance of common stock under the employee stock purchase plan
from December 31, 2018 to March 31, 2019 Issuance of common stock upon the exercise of pre-funded warrants Issuance of restricted stock
from December 31, 2017 to December 31, 2018 Cash paid in lieu of fractional shares for 1:10 reverse stock split Issuance of common stock under 2017 Lincoln Park Capital, LLC purchase agreement Issuance of common stock and warrants in connection with registered direct offering and private placement, net of offering costs of $690 Issuance of common stock, pre-funded warrants and warrants in connection with underwritten public offering, net of offering costs of $1,630 Issuance of common stock upon the exercise of pre-funded warrants Issuance of common stock under employee stock purchase plan Issuance of unvested, restricted stock
RXi Pharmaceuticals Corporation today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 12:01 a.m. Eastern Time on January 8, 2018, and shares of RXi Pharmaceuticals common stock will trade on a post-split basis on the Nasdaq Capital Market under the Company’s existing trading symbol, “RXII,” at the market open on January 8, 2018.At the effective time of the reverse stock split, every ten (10) shares of RXi Pharmaceuticals common stock will be combined into one (1) share of RXi Pharmaceuticals common stock. This will reduce the Company’s issued and outstanding common stock from approximately 24.3 million shares to approximately 2.4 million shares.
From December 31, 2015 to December 31, 2016 Issuance of common stock under Lincoln Park Capital, LLC purchase agreement Issuance of common stock and warrants in connection with 2016 public offering, net of offering costs of $431 Issuance of Series B convertible preferred stock and warrants in connection with 2016 public offering, net of offering costs of $1,018 Conversions of Series B convertible preferred stock into common stock RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10.
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10.
From December 31, 2014 to December 31, 2015 Issuance of common stock under Lincoln Park Capital, LLC purchase agreement Issuance of common stock in exchange for patent and technology rights Issuance of common stock in connection with public offering, net of offering costs of $1,198 Issuance of common stock under employee stock purchase plan Issuance of common stock upon exercise of warrants in connection with public offering Dividends issued on Series A and Series A-1 convertible preferred stock Exchange of Series A convertible preferred stock into Series A-1 convertible preferred stock Conversions of Series A and Series A-1 convertible preferred stock into common stock
from December 31, 2013 to December 31, 2014 Exchange of Series A convertible preferred stock into Series A-1 convertible preferred stock Conversions of Series A and Series A-1 convertible preferred stock into common stock Dividends issued on Series A and Series A-1 convertible preferred stock Issuance of common stock, net of offering costs of $114 Issuance of common stock under employee stock purchase plan
from December 31,2012 to December 31,2013 Exchange of Series A convertible preferred stock into Series A-1 convertible preferred stock Conversions of Series A and Series A-1 convertible preferred stock into common stock Dividends issued on Series A and Series A-1 convertible preferred stock Issuance of common stock, net of offering costs of $727 Issuance of common stock in exchange for patent and technology rights Cash paid in lieu of fractional shares for 1:30 reverse stock split Common stock issued upon exercise of stock options Issuance of common stock under employee stock purchase plan
from December 31, 2012 to September 30, 2013 Exchange of Series A convertible preferred stock into Series A-1 convertible preferred stock Conversions of Series A and Series A-1 convertible preferred stock into common stock Dividends issued on Series A and Series A-1 convertible preferred stock Issuance of common stock, net of offering costs of $727 Issuance of common stock in exchange for patent and technology rights Cash paid in lieu of fractional shares for 1:30 reverse stock split Common stock issued upon exercise of stock options
同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。

【免责声明】本产品中的行情数据及资讯信息来源于第三方，长江证券不对收集数据的版权、真实性、准确性及传输过程中发生的传送错误承担法律责任。本内容仅供参考，不作为投资决策依据，长江证券不对因据此操作产生的盈亏承担任何责任。投资有风险，入市需谨慎。